Pfizer and Sangamo report positive data from hemophilia A trial

Pfizer world headquarters entrance
Giroctocogene fitelparvovec is being developed as part of an agreement between Sangamo and Pfizer for the global development of gene therapies for hemophilia A. Credit: Coolcaesar.